| CAS | 211439-12-2 |
| Sequence | H-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH |
| Sequence Single | NAPVSIPQ |
| Molecular Formula | C36H60N10O12 |
| Molecular Weight | 824.93 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Description | Davunetide is a highly potent active component of activity-dependent neuroprotective protein (ADNP). Davunetide prevents β-amyloid aggregation. Davunetide reduces hyperphosphorylated tau levels and increases tau-microtubule interactions; Davunetide is neuroprotective at femtomolar concentrations in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. |
| References | 1. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Bassan et al (1999). J.Neurochem. 72 1283 PMID: 10037502 2. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze J. Gozes et al (2000). Pharmacol.Exp.Ther. 293 1091 PMID: 10869414 3. ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer’s Disease. Sragovich et al (2017). Bioessays 39 doi: 10.1002 PMID: 28940660 4. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson’s disease. Melo et al (2017). Exp.Brain Res. 235 731 PMID: 27866262 5. NAP counteracts hyperglycemia/hypoxia induced retinal pigment epithelial barrier breakdown through modulation of HIFs and VEGF expression. D’Amico et al (2018). J.Cell Physiol. 233 1120 PMID: 28436035 6. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Ivashko-Pachima et al (2017). Mol Psychiatry 22 1335 PMID: 28115743 |